What is the current stock price of EyePoint Pharmaceuticals, Inc. (EYPT)?

As of the latest market data, EyePoint Pharmaceuticals, Inc. (EYPT) is trading at $14.19. The stock has seen a loss of -0.28% today.

Does EyePoint Pharmaceuticals, Inc. (EYPT) pay a dividend?

Based on current data, EyePoint Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of EyePoint Pharmaceuticals, Inc.?

The current market capitalization of EyePoint Pharmaceuticals, Inc. (EYPT) is approximately unavailable.

EYPT

EyePoint Pharmaceuticals, Inc.·Healthcare

14.19

0.281%(−0.04)

Market Closed

14.47

1.973%(+0.28)

After Hours

Last Updated: — ET

52W L: $5.1452W H: $19.11

EYPT NEWS

defenseworld.net

5d ago

Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) by 101.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,605,984 shares of the company's stock after purchasing an additional 809,182 shares during the quarter. Aberdeen Group plc owned

defenseworld.net

Mar 27

EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference

Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four Phase 3 studies in retinal disease, with the first top-line readout expected around August. Lead program and Phase 3 timeline Chief Executive Officer Jay Duker said DURAVYU is a small-molecule tyrosine

globenewswire.com

Mar 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

fool.com

Mar 15

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.

defenseworld.net

Mar 13

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating on the

seekingalpha.com

Mar 4

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

Company Profile

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

165

IPO Date

2005-01-27

Beta

1.91

Websiteeyepointpharma.com↗